Bert Vogelstein
Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.
With Kenneth Kinzler, defined the adenoma-carcinoma sequence, discovered p53's tumour-suppressor role, sequenced the first cancer genomes, and developed CancerSEEK, the basis of multi-cancer blood testing.
| Title | Journal | Year |
|---|---|---|
| Cancer genome landscapes | Science | 2013 |
| Detection and localization of surgically resectable cancers with a multi-analyte blood test | Science | 2018 |
For stage II colon cancer, where most patients are cured by surgery alone, a blood test can identify the minority who benefit from chemotherapy and spare everyone else its side effects. It does not yet prove that treating ctDNA-positive patients improves survival compared with not treating them.
A blood test can find early, treatable cancers in people who feel well, including cancers for which no screening exists. It is not a replacement for mammography or colonoscopy but a possible addition. Larger randomised trials are needed to show benefit outweighs harm.
There are not thousands of cancer genes, and any one patient's tumour is driven by only a few of them. That makes targeted sequencing panels sensible, but because most drivers are lost tumour suppressors, drugs exist for only a minority, which is why the same group turned to early detection.
Pages like this
not linked directly; found by shared links- PersonKenneth W. Kinzler
Shares DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms, Lustgarten Foundation, Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer.
- PersonAnirban Maitra
Shares Multi-cancer early detection (MCED), KRAS, Liquid biopsy (ctDNA), Pancreatic ductal adenocarcinoma.
- PersonAndrew J. Aguirre
Shares Lustgarten Foundation, KRAS, Pancreatic ductal adenocarcinoma.
- IdeaCheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares TP53, KRAS, Pancreatic ductal adenocarcinoma.
- PersonDung T. Le
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductMRTX1133
Shares KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductOlomorasib
Shares KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.